Kiromic BioPharma surges on research agreement to expand cancer therapy pipeline

Kiromic Biopharma

07/06/2022 12:52

** Shares of gene-editing company Kiromic BioPharma  KRBP.O 
rise ~135.7% to $0.66 premarket - top pct gainer across U.S.
exchanges
    ** Co enters into a sponsored research agreement to expand
its cancer therapy product pipeline  urn:newsml:reuters.com:*:nBw6S5WYha
    ** Under the two-year agreement, in vivo preclinical data
will be generated from Kiromic's cancer treatment candidates
Procel, Isocel, and Deltacel
    ** Data is intended to support clinical trial applications
to U.S. FDA for these candidates
    ** Stock had lost ~82% YTD, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))